Discover
DRTS
Alpha Tau Medical Ltd.
14.41
2 x 10.30
2 x 18.16
bid
ask
+
0.41
2.93%
2 @ 06:52 PM
14.45 +0.04 (0.28%)
| Ytd | 191.11% | |
| 1y | 272.35% |
13.99
day range
14.50
3.47
52 week range
15.50
| Open | 14.00 | Prev Close | 14.00 | Low | 13.99 | High | 14.50 | Mkt Cap | 1.33B |
| Vol | 368.20K | Avg Vol | 569.89K | EPS | -1.04 | P/E | N/A | Forward P/E | -26.96 |
| Beta | 1.22 | Short Ratio | 5.72 | Inst. Own | 9.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-19 | 50-d Avg | 14.32 | 200-d Avg | 9.99 | 1yr Est | 17.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-19 | 2026-09 | -0.14 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.14 | -0.5 | -0.36 | -254.91% |
| 2026-05-18 | 2026-03 | -0.13 | -0.26 | -0.13 | -100.00% |
| 2026-03-09 | 2025-12 | -0.13 | -0.14 | -0.01 | -7.69% |
| 2025-11-20 | 2025-09 | -0.12 | -0.14 | -0.02 | -16.67% |
| 2025-08-11 | 2025-06 | -0.12 | -0.13 | -0.01 | -8.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-03 | Barclays | Upgrade | Overweight | Overweight |
| 2026-08-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | Barclays | Upgrade | Overweight | Overweight |
Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-20 | LEVY RAPHI | Chief Financial Officer | 90.18K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Gem Investment Advisors, LLC | 1.43M | 20.67M | 2.07% |
| 2026-06-29 | HighTower Advisors, LLC | 874.99K | 12.61M | 1.26% |
| 2026-06-29 | Boothbay Fund Management, LLC | 773.48K | 11.15M | 1.12% |
| 2026-06-29 | Aquamarine Financial (cayman) Ltd | 721.50K | 10.40M | 1.04% |
| 2026-06-29 | Pier Capital, LLC | 691.94K | 9.97M | 1.00% |
| 2026-06-29 | UBS Group AG | 642.26K | 9.26M | 0.93% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | iShares Trust-iShares Core MSCI EAFE ETF | 464.45K | 6.69M | 0.67% |
| 2026-08-30 | iShares Trust-iShares MSCI EAFE Small-Cap ETF | 204.25K | 2.94M | 0.29% |
| 2026-08-30 | ARK ETF Trust-ARK Israel Innovative Technology ETF | 184.38K | 2.66M | 0.27% |
| 2026-08-30 | RBB Fund, Inc.-Adara Smaller Companies Fund | 134.70K | 1.94M | 0.19% |
| 2026-08-30 | iShares, Inc.-iShares MSCI Israel ETF | 134.22K | 1.93M | 0.19% |
| 2026-07-30 | Dunham Funds-Dunham Small Cap Growth Fund | 71.66K | 1.03M | 0.10% |